Nutrition (all articles)
SR | Little to no impact of low glycemic index/glycemic load diets on weight loss in overweight or obese individuals
30 Jun, 2023 | 14:54h | UTCSummary: This systematic review examined the impact of low glycaemic index or load (GI/GL) diets on weight loss in overweight or obese individuals, analyzing data from 10 randomized controlled trials (RCTs), with 1,210 participants. The main outcomes included changes in body weight, body mass index (BMI), adverse events, health-related quality of life, and mortality. The study showed that low GI/GL diets probably result in little to no difference in body weight and BMI changes compared to higher GI/GL diets or other diets. The evidence suggests a lack of effect on all main outcomes and the possible positive influence on mood remains uncertain.
The studies included in this review had a small sample size with a moderate to very low certainty of evidence. This suggests more well-structured studies with larger sample sizes are needed for firmer conclusions. Limitations of this review included the risk of bias, as many of the studies did not adopt objective outcome measurements and some had a high degree of loss to follow-up. Furthermore, the researchers recommend that future studies focus on diverse demographic groups and include participants from low- and middle-income countries.
Phase 2 RCT | Triple-hormone-receptor (GIP, GLP-1, and glucagon) agonist Retatrutide substantially reduces body weight in obesity
28 Jun, 2023 | 13:23h | UTCSummary: This Phase 2, double-blind, randomized, placebo-controlled trial evaluated the efficacy and safety of Retatrutide, a triple-hormone-receptor agonist of GIP, GLP-1, and glucagon, for obesity treatment. The study recruited 338 adults, predominantly male, with a Body Mass Index (BMI) of 30 or higher, or 27 to 30 with at least one weight-related condition. Participants were administered subcutaneous Retatrutide at varying doses or a placebo, once weekly for 48 weeks.
The findings indicate a dose-dependent weight loss efficacy for Retatrutide. At 24 weeks, Retatrutide users exhibited a mean body weight decrease ranging from 7.2% (1 mg dose) to 17.5% (12 mg dose), compared to a 1.6% reduction in the placebo group. This effect was even more pronounced at 48 weeks, with changes ranging from 8.7% (1 mg dose) to a striking 24.2% (12 mg dose), contrasted with a 2.1% reduction in the placebo group. Adverse events, primarily gastrointestinal, were common with Retatrutide, reported by 73 to 94% of patients, and were dose-related.
Retatrutide demonstrated substantial body weight reduction in adults with obesity, with a side effects profile similar to existing GLP-1 and GIP–GLP-1 receptor agonists. These promising results warrant further investigation through a Phase 3 trial to further ascertain the safety and efficacy of Retatrutide in obesity treatment.
Article: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Late breaking at #ADA23: In this trial involving participants with obesity, 48 weeks of treatment with retatrutide, an agonist of the GIP, GLP-1, and GCG receptors, resulted in substantial reductions in body weight. https://t.co/jNL1GNna0l
— NEJM (@NEJM) June 26, 2023
Phase 2 RCT | Triple receptor agonist (GIP, GLP-1 and glucagon) Retatrutide shows promising results in obese patients with T2DM
28 Jun, 2023 | 13:21h | UTCSummary: A Phase 2 Randomized Clinical Trial (RCT) was conducted to investigate the efficacy and safety of Retatrutide, a glucose-dependent insulinotropic polypeptide (GIP), GLP-1, and glucagon receptor agonist, in patients with type 2 diabetes. The study involved 281 adults aged between 18 and 75 years with type 2 diabetes. These patients, with a mean HbA1c level of 8·3%, a mean BMI of 35·0 kg/m², and a mean body weight of 98·2 kg, were randomized to Retatrutide at various doses, Dulaglutide 1.5 mg, and placebo. Patients were treated with diet and exercise alone or a stable dose of metformin for at least three months prior to the study.
The primary outcomes revealed that at 24 weeks, participants who received the higher doses of Retatrutide demonstrated substantial improvements in HbA1c compared to the placebo group and those who received Dulaglutide. Specifically, for the highest-dose Retatrutide group (12 mg), HbA1c level was reduced by an average of 2.02%, which was significantly greater compared to a reduction of 0.01% in the placebo group and 1.41% in the Dulaglutide group.
Regarding body weight, at 36 weeks, participants receiving the different doses of Retatrutide showed a dose-dependent decrease: 3.19% for the 0.5 mg group, 7.92% for the 4 mg escalation group, 10.37% for the 4 mg group, 16.81% for the 8 mg slow escalation group, 16.34% for the 8 mg fast escalation group, and 16.94% for the 12 mg escalation group. This was significantly higher compared to the 3.00% weight loss in the placebo group and the 2.02% loss with 1.5 mg Dulaglutide.
Mild-to-moderate gastrointestinal adverse events were reported among 35% of the participants in the Retatrutide groups, similar to those in the Dulaglutide group, and no severe hypoglycemia or deaths were reported.
The implications of these findings suggest that Retatrutide provides clinically meaningful improvements in glycaemic control and bodyweight reduction with a safety profile consistent with GLP-1 receptor agonists and GIP and GLP-1 receptor agonists. Limitations of the study include limitation of this study is the relatively short duration of the trial and small sample size. Long-term effects and safety of Retatrutide remain to be evaluated in further studies.
Article: Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA – The Lancet (link to abstract – $ for full-text)
Phase 2 RCT | Orforglipron, an oral GLP-1 receptor agonist, significantly reduces weight in adults with obesity
26 Jun, 2023 | 00:58h | UTCSummary: The article reports a phase 2, randomized, double-blind trial investigating the efficacy of the GLP-1 receptor agonist, orforglipron, as an oral weight loss treatment for adults with obesity or overweight plus at least one weight-related condition. The study involved 272 participants, who were administered orforglipron at varying doses or a placebo over a 36-week period.
The key findings of the study indicated significant weight reduction in individuals who were administered orforglipron. At 26 weeks, weight changes in the orforglipron group ranged from -8.6% to -12.6% compared to -2.0% in the placebo group. At 36 weeks, these figures were -9.4% to -14.7% for the orforglipron group and -2.3% for the placebo group. Furthermore, 46-75% of orforglipron recipients experienced a weight reduction of at least 10% by week 36, compared to 9% in the placebo group.
Improvements were also observed in all prespecified weight-related and cardiometabolic measures among orforglipron users. However, the treatment was associated with some mild to moderate gastrointestinal side effects, leading to discontinuation in 10-17% of participants. The safety profile was in line with other GLP-1 receptor agonists. These findings suggest that orforglipron could potentially be an effective oral treatment for weight reduction in adults with obesity, though further research is needed to corroborate these results and assess long-term effects.
Article: Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity – New England Journal of Medicine (link to abstract – $ for full-text)
Review | The role of diet and nutrition in the management of COPD
19 Jun, 2023 | 13:47h | UTCThe role of diet and nutrition in the management of COPD – European Respiratory Review
Pre-clinical Study | Taurine deficiency and aging, a correlation found in mice, monkeys, and worms
12 Jun, 2023 | 13:53h | UTCTaurine deficiency as a driver of aging – Science
Invited Commentary: Taurine linked with healthy aging – Science
News Release: Taurine May Be a Key to Longer and Healthier Life – Columbia University
Commentary on Twitter
Taurine deficiency may be a driver for aging, finds a new Science study in several animal models. The results warrant clinical trials to examine taurine’s effect on healthy lifespan in humans.
?: https://t.co/iJfI4rne7o#SciencePerspective: https://t.co/EdOKecgoqF pic.twitter.com/dekChiKRN3
— Science Magazine (@ScienceMagazine) June 8, 2023
RCT | Multivitamin supplementation may improve memory in aged adults
7 Jun, 2023 | 14:12h | UTCMultivitamin Supplementation Improves Memory in Older Adults: A Randomized Clinical Trial – The American Journal of Clinical Nutrition (link to abstract – $ for full-text)
News Releases:
Multivitamin Improves Memory in Older Adults, Study Finds – Columbia University
Related Research: Effects of cocoa extract and a multivitamin on cognitive function: A randomized clinical trial – Alzheimer’s & Dementia
SR | Limited evidence for vitamin and mineral supplements in delaying dementia in people with mild cognitive impairment
7 Jun, 2023 | 14:09h | UTC
Commentary on Twitter
? How does vitamin and mineral supplementation affect #cognitivefunction and progression to #dementia in people with mild cognitive impairment (MCI)?
Get the current evidence picture in this #systematicreview on @CochraneLibrary: https://t.co/YUsbjELIZq@NIH_ODS #NSHFD pic.twitter.com/hRl27Tm7op— Cochrane CAM (@CochraneCAM) May 31, 2023
Effects of ketogenic diet on health outcomes: an umbrella review of meta-analyses of randomized clinical trials
1 Jun, 2023 | 11:56h | UTC
M-A | Plant-based diets reduce key atherogenic lipoproteins
30 May, 2023 | 11:48h | UTCEditorial: Plant-based dietary patterns and atherogenic lipoproteins – European Heart Journal
Review | Child and adolescent obesity
30 May, 2023 | 11:45h | UTCChild and adolescent obesity – Nature Reviews Disease Primers (if the link is paywalled, try this one)
Commentary on Twitter
A Primer in @DiseasePrimers discusses the epidemiology, mechanisms, diagnosis, prevention and management of obesity in children and adolescents, highlighting patient quality of life and areas for further research. https://t.co/Zpcb4RbH2J pic.twitter.com/uneXxVyTDg
— Nature Portfolio (@NaturePortfolio) May 28, 2023
Review | Nutritional epidemiology and dietary assessment for patients with kidney disease
29 May, 2023 | 10:43h | UTC
M-A | Optimizing enteral nutrition delivery by implementing volume-based feeding protocol for critically ill patients
24 May, 2023 | 13:13h | UTC
Opinion Video | Questioning the reliability of nutrition science
23 May, 2023 | 13:02h | UTC
WHO advises not to use non-sugar sweeteners for weight control in newly released guideline
16 May, 2023 | 15:04h | UTCNews Release: WHO advises not to use non-sugar sweeteners for weight control in newly released guideline – World Health Organization
WHO Guideline: Use of non-sugar sweeteners – World Health Organization
Meta-Analysis: Health effects of the use of non-sugar sweeteners – World Health Organization
M-A | Evaluation of the effectiveness of telehealth chronic disease management system
16 May, 2023 | 14:55h | UTC
Review | Nonalcoholic fatty liver disease from a primary care perspective
15 May, 2023 | 12:57h | UTCNonalcoholic fatty liver disease from a primary care perspective – Diabetes, Obesity and Metabolism
M-A | Adding exercise to hypocaloric diet doesn’t enhance weight loss or glycemic control in T2D patients
15 May, 2023 | 12:52h | UTC
M-A | Fruit and vegetable consumption and the risk of hypertension
11 May, 2023 | 12:02h | UTC
M-A | Prevalence and outcomes of frailty in unplanned hospital admissions
9 May, 2023 | 14:45h | UTC
Evidence-based recommendations for the dietary management of diabetes
8 May, 2023 | 12:56h | UTCEvidence-based European recommendations for the dietary management of diabetes – Diabetologia (if the link is paywalled, try this one)
AHA Scientific Statement | Assessing popular diets in relation to 2021 American Heart Association dietary recommendations
28 Apr, 2023 | 13:21h | UTCTop Things to Know: Popular Dietary Patterns: Alignment with AHA 2021 Dietary Guidance – American Heart Association
Commentary on Twitter
A ? scientific statement evaluates how well 10 popular eating patterns align with AHA nutrition guidance, offering a valuable tool for both clinicians and consumers to understand and adopt heart-healthy dietary patterns.
Read more ? https://t.co/PbGRqhF05p pic.twitter.com/sropKchRWx— AHA Science (@AHAScience) April 27, 2023
Cohort Study | Beverage consumption and mortality among adults with type 2 diabetes
26 Apr, 2023 | 14:09h | UTCEditorial: Beverages and health outcomes in adults with type 2 diabetes – The BMJ
Commentary: Healthy Beverage Choices May Lower Mortality Risk in Adults with Diabetes – HCP Live
Review | What the clinician needs to know about medical nutrition therapy in critically ill patients in 2023
26 Apr, 2023 | 13:59h | UTC
RCT | Bariatric–metabolic surgery is more effective than lifestyle intervention plus best medical care in non-alcoholic steatohepatitis
24 Apr, 2023 | 14:03h | UTCNews Release: Surgery most effective treatment of metabolic liver disease – King’s College London
Commentary on Twitter
New @TheLancet – Verrastro et al – Bariatric–metabolic surgery versus lifestyle intervention plus best medical care in non-alcoholic steatohepatitis (BRAVES): a multicentre, open-label, randomised trialhttps://t.co/pCWahvbReQ#NASH #NAFLD #fattyliver #livertwitter pic.twitter.com/xNMsAskJF9
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) April 21, 2023